Trial Profile

A Randomized, Open-Label, Phase 3 Study of Rinatabart Sesutecan (Rina-S) Plus Standard of Care Versus Standard of Care as Maintenance Treatment After 2L Platinum-Based Doublet Chemotherapy in Participants With Recurrent Platinum-Sensitive Ovarian Cancer (PSOC)

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 15 Sep 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rinatabart sesutecan (Primary) ; Bevacizumab
Indications Adenocarcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
Focus Registrational; Therapeutic Use
Acronyms RAINFOL-04
Sponsors Genmab

17 Jul 2026 Planned number of patients changed from 528 to 544.
17 Jul 2026 Planned End Date changed from 1 Apr 2030 to 1 May 2030.
21 May 2026 According to a Genmab media release, data from this study will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com